Search - tctmd.com

Displaying 81 - 100 of 818

Sort: Relevancy | Date

Presentation TCT 2025

Sirolimus-Eluting Balloon Versus Repeat Drug-Eluting Stenting or Balloon Angioplasty for In-stent Restenosis

Presenter: Donald Cutlip

October 26, 2025

Presentation TCT 2025

Commentary

Presenter: Fernando Alfonso

October 26, 2025

Presentation TCT 2025

One-Year Results of the SELUTION DeNovo Trial Comparing a Strategy of PCI with a Sirolimus-eluting Balloon and Provisional Stenting Versus Systematic DES Implantation to Treat DeNovo Coronary Lesions

Presenter: Christian M. Spaulding

October 26, 2025

News Conference News TCT 2025

Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

Caitlin E. Cox

October 25, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2024

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Yael L. Maxwell

November 07, 2024

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe

Caitlin E. Cox

October 30, 2024

News Conference News TCT 2024

Preprocedural AI-QCA Matches OCT-Guided PCI for Noncomplex Lesions

Yael L. Maxwell

October 30, 2024

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Todd Neale

October 30, 2024

Presentation TCT 2024

Clinical Outcomes Following Sirolimus-Eluting Iron Bioresorbable Scaffold Implantation: One-Year Follow-Up of the Patient-Level Pooled Analysis from the IRONMAN II and III Trials

Presenter: Lei Song

October 30, 2024

Presentation TCT 2024

Patient-Reported Outcomes are a True Measure of TTVI Value

Presenter: John Spertus

October 30, 2024

Presentation TCT 2024

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

Presenter: Ori Ben-Yehuda

October 30, 2024

Presentation TCT 2024

Artificial Intelligence-Based Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH)

Presenter: Jung-Min Ahn

October 30, 2024

Presentation TCT 2024

Editorial Comments

Presenter: Akiko Maehara

October 30, 2024

Presentation TCT 2024

Late Clinical Outcomes in Small Annulus Patients in the PARTNER Trials

Presenter: Mahesh Madhavan

October 30, 2024

Presentation TCT 2024

TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

Presenter: Susheel Kodali

October 30, 2024

Presentation TCT 2024

Editorial Comments

Presenter: Vinayak Bapat

October 30, 2024

Advertisement

Sirolimus-Eluting Balloon Versus Repeat Drug-Eluting Stenting or Balloon Angioplasty for In-stent Restenosis

Commentary

One-Year Results of the SELUTION DeNovo Trial Comparing a Strategy of PCI with a Sirolimus-eluting Balloon and Provisional Stenting Versus Systematic DES Implantation to Treat DeNovo Coronary Lesions

Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

What’s Going to Be Hot at TCT 2025

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe

Preprocedural AI-QCA Matches OCT-Guided PCI for Noncomplex Lesions

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Clinical Outcomes Following Sirolimus-Eluting Iron Bioresorbable Scaffold Implantation: One-Year Follow-Up of the Patient-Level Pooled Analysis from the IRONMAN II and III Trials

Patient-Reported Outcomes are a True Measure of TTVI Value

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

Artificial Intelligence-Based Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH)

Editorial Comments

Late Clinical Outcomes in Small Annulus Patients in the PARTNER Trials

TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

Editorial Comments

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content